RxDoctor Payments Data

Sixto Lirio, MD

Family Medicine · Cape May Court House, NJNPI 1780683672

Payments from drug & device makers

$2,638in general payments, 2019–2025

Across 88 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$859
  • SK Life Science, Inc.$289
  • Acadia Pharmaceuticals Inc$245
  • Novo Nordisk$211
  • Sumitomo Pharma America, Inc.$186
  • Sunovion Pharmaceuticals Inc.$186
  • plus $662 from 13 others

What the payments were for

  • Food & beverage$2,638100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,638 in reported general payments places this provider in the 80th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$64,562
Medicare patients
143
Services billed
522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide112$63,084
NuplazidPimavanserin Tartrate15$62,850
ProliaDenosumab32$58,586
EliquisApixaban119$51,535
TrulicityDulaglutide32$32,982
CreonLipase/Protease/Amylase20$31,102
RybelsusSemaglutide24$24,048
XcopriCenobamate25$23,946
BriviactBrivaracetam13$19,312
VersaclozClozapine22$19,214
SecuadoAsenapine12$17,266
JanuviaSitagliptin Phosphate36$14,341
Esomeprazole Magnesium86$13,429
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,337
Famotidine88$10,987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$32$94,187132 claims
Acadia Pharmaceuticals IncNuplazid$245$62,85015 claims
AmgenProlia$15$58,58632 claims
PfizerEliquis$32$51,535119 claims
Lilly USA, LLCTrulicity$39$32,98232 claims
Novo NordiskRybelsus, Fiasp$211$29,07540 claims
UCB, Inc.Briviact, Nayzilam$97$28,80027 claims
SK Life Science, Inc.Xcopri$289$23,94625 claims
Sumitomo Pharma America, Inc.Gemtesa$186$4,89620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Cape May Court House

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →